{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:17:43Z","timestamp":1790918263725,"version":"4.1.0"},"reference-count":62,"publisher":"Japanese Society for the Study of Xenobiotics","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2011]]},"DOI":"10.2133\/dmpk.dmpk-10-rv-090","type":"journal-article","created":{"date-parts":[[2010,12,17]],"date-time":"2010-12-17T05:20:19Z","timestamp":1292563219000},"page":"60-70","source":"Crossref","is-referenced-by-count":39,"title":["Drug-Induced Idiosyncratic Hepatotoxicity: Prevention Strategy Developed after the Troglitazone Case"],"prefix":"10.2133","volume":"26","author":[{"given":"Toshihiko","family":"Ikeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"900","reference":[{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0005","first-page":"461","article-title":"Liver dysfunction associated with troglitazone (Noscal)","volume":"14","author":"Kuramoto","year":"1998","journal-title":"J. Clin. Ther. Med."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0010","first-page":"537","article-title":"Was it not possible to predict liver dysfunction caused by troglitazone during the nonclinical safety studies?","volume":"30","author":"Watanabe","year":"1999","journal-title":"Reevaluation of safety. Iyakuhin Kenkyu"},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0015","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/978-3-642-00663-0_14","volume":"196","author":"Yokoi","year":"2010","journal-title":"Troglitazone. Handb. Exp. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2133\/dmpk.DMPK-10-RV-085","article-title":"Involvement of the immune system in idiosyncratic drug reactions","volume":"26","author":"Zhang","year":"2011","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1289\/ehp.76153","article-title":"Various forms of chemically induced liver injury and their detection by diagnostic procedures","volume":"15","author":"Zimmerman","year":"1976","journal-title":"Environ. Health Perspect."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.tox.2005.07.012","article-title":"Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction","volume":"216","author":"Maniratanachote","year":"2005","journal-title":"Toxicology"},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0035","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1517\/17425255.2.4.493","article-title":"Role of innate immunity in acetaminophen-induced hepatotoxicity","volume":"2","author":"Liu","year":"2006","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0040","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1056\/NEJM198007103030202","article-title":"Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis","volume":"303","author":"Vergani","year":"1980","journal-title":"N. Engl. J. Med."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0045","first-page":"356","article-title":"Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs","volume":"47","author":"Kawai","year":"1997","journal-title":"Arzneimittelforschung"},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0050","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1021\/tx000180q","article-title":"Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission","volume":"14","author":"Kassahun","year":"2001","journal-title":"Chem. Res. Toxicol."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0055","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1124\/dmd.30.2.155","article-title":"Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells","volume":"30","author":"Yamamoto","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0060","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1124\/dmd.32.6.639","article-title":"Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved","volume":"32","author":"He","year":"2004","journal-title":"Drug Metab. Dispos."},{"issue":"Suppl. 2","key":"10.2133\/dmpk.DMPK-10-RV-090_bb0065","first-page":"204","article-title":"Covelent adducts in human primary hepatocytes cultured with \u00aa14C]troglitazone","volume":"32","author":"Sato","year":"2000","journal-title":"Drug Metab. Rev."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0070","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2174\/187231208785425773","article-title":"Troglitazone thiol adduct formation in human liver microsomes: enzyme kinetics and reaction phenotyping","volume":"2","author":"Gan","year":"2008","journal-title":"Drug Metab. Lett."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0075","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/S0090-9556(24)15045-3","article-title":"Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes","volume":"27","author":"Ramachandran","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0080","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/004982500237668","article-title":"Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes","volume":"30","author":"Sahi","year":"2000","journal-title":"Xenobiotica"},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0085","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/00912709922007985","article-title":"Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent","volume":"39","author":"Loi","year":"1999","journal-title":"J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0090","first-page":"1037","article-title":"Rezulin (troglitazone) greatly increases cyclosporine metabolism","volume":"17","author":"Frantz","year":"1998","journal-title":"J. Heart Lung Transplant."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0095","first-page":"1139","article-title":"Troglitazone, a new antidiabetic agent, decreases cyclosporine level","volume":"17","author":"Park","year":"1998","journal-title":"J. Heart Lung Transplant."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0100","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/j.1552-4604.1998.tb00014.x","article-title":"Effect of troglitazone on urinary excretion of 6\u03b2-hydroxycortisol","volume":"38","author":"Koup","year":"1998","journal-title":"J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0105","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0009-9236(03)00014-6","article-title":"A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus","volume":"73","author":"Watanabe","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0110","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/hep.22370","article-title":"Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury","volume":"48","author":"Lucena","year":"2008","journal-title":"Hepatology"},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0115","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.110.034652","article-title":"Direct and rapid genotyping of glutathione-S-transferase M1 and T1 from human blood specimens using the SmartAmp2 method","author":"Okada","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0120","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0125","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLAB*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0130","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.tpj.6500442","article-title":"Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study","volume":"8","author":"Hirata","year":"2008","journal-title":"Pharmacogenomics J."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0135","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ng.379","article-title":"HLAB*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin","volume":"41","author":"Daly","year":"2009","journal-title":"Nat. Genet."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0140","series-title":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Information for healthcare professionals, Carbamazepine (marketed as carbatrol, equetro, tegretol, and generics)","year":"2007"},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0145","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0150","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.tpj.6500356","article-title":"A marker for Stevens Johnson syndrome: ethnicity matters","volume":"6","author":"Lonjou","year":"2006","journal-title":"Pharmacogenomics J."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0155","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with anti-epileptics and allopurinolrelated Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0160","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2133\/dmpk.25.122","article-title":"Prediction of severe adverse drug reactions using pharmacogenetic biomarkers","volume":"25","author":"Tohkin","year":"2010","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0165","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.4049\/jimmunol.158.3.1473","article-title":"The role of hepatitis C virusspecific cytotoxic T lymphocytes in chronic hepatitis C","volume":"158","author":"Nelson","year":"1997","journal-title":"J. Immunol."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0170","doi-asserted-by":"crossref","first-page":"5283","DOI":"10.4049\/jimmunol.158.11.5283","article-title":"Perforin, Fas\/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL","volume":"158","author":"Ando","year":"1997","journal-title":"J. Immunol."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0175","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1146\/annurev.iy.12.040194.005015","article-title":"Tolerance, danger, and the extended family","volume":"12","author":"Matzinger","year":"1994","journal-title":"Annu. Rev. Immunol."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0180","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1021\/tx980249i","article-title":"New concepts in immunology relevant to idiosyncratic drug reactions: the \u00fadanger hypothesis\u201d and innate immune system","volume":"12","author":"Uetrecht","year":"1999","journal-title":"Chem. Res. Toxicol."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0185","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/tx700186p","article-title":"Idiosyncratic drug reactions: past, present, and future","volume":"21","author":"Uetrecht","year":"2008","journal-title":"Chem. Res. Toxicol."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0190","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/S0024-3205(01)00985-7","article-title":"Toxic effect of troglitazone on cultured rat hepatocytes","volume":"68","author":"Toyoda","year":"2000","journal-title":"Life Sci."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0195","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s002040100251","article-title":"Thiazolidinedione toxicity to isolated hepatocytes revealed by coherent multiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral leukocytes","volume":"75","author":"Haskins","year":"2001","journal-title":"Arch. Toxicol."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0200","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0024-3205(01)01432-1","article-title":"Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells","volume":"70","author":"Yamamoto","year":"2001","journal-title":"Life Sci."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0205","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.taap.2009.07.021","article-title":"Troglitazone, but not rosiglitazone, damages mitochondrial DNA and induces mitochondrial dysfunction and cell death in human hepatocytes","volume":"240","author":"Rachek","year":"2009","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0210","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1124\/mol.59.3.627","article-title":"Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat","volume":"59","author":"Funk","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0215","series-title":"Cytochrome P450 and Other Enzyme in Drug Discovery and Development","first-page":"147","article-title":"Drug Metabolizing Enzymes","author":"Baillie","year":"2003"},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0220","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/tx034170b","article-title":"Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development","volume":"17","author":"Evans","year":"2004","journal-title":"Chem. Res. Toxicol."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0225","first-page":"55","article-title":"Precition of a new drug\u00f6s potential to cause idiosyncratic reactions","volume":"4","author":"Uetrecht","year":"2001","journal-title":"Curr. Opin. Drug Discov. Dev."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0230","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2133\/dmpk.19.55","article-title":"Utility of microtiter plate assays for human cytochrome P450 inhibition studies in drug discovery: application of simple method for detecting quasi-irreversible and irreversible inhibitors","volume":"19","author":"Naritomi","year":"2004","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0235","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1002\/rcm.2195","article-title":"Rapid detection and characterization of minor reactive metabolites using stable-isotope trapping in combination with tandem mass spectrometry","volume":"19","author":"Yan","year":"2005","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0240","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1002\/rcm.2223","article-title":"Application of stable isotope labeled glutathione and rapid scanning mass spectrometers in detecting and characterizing reactive metabolites","volume":"19","author":"Mutlib","year":"2005","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0245","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1021\/tx049741u","article-title":"Negative ion tandem mass spectrometry for the detection of glutathione conjugates","volume":"18","author":"Dieckhaus","year":"2005","journal-title":"Chem. Res. Toxicol."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0250","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1021\/tx060234h","article-title":"Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans","volume":"20","author":"Masubuchi","year":"2007","journal-title":"Chem. Res. Toxicol."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0255","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2133\/dmpk.24.100","article-title":"Quantitative assessment of reactive metabolite formation using 35S-labeled glutathione","volume":"24","author":"Takakusa","year":"2009","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0260","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1021\/tx800368n","article-title":"In vitro screening of 50 highly prescribed drugs for thiol adduct formation-comparison of potential for drug-induced toxicity and extent of adduct formation","volume":"22","author":"Gan","year":"2009","journal-title":"Chem. Res. Toxicol."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0265","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1021\/tx9700174","article-title":"Characterization of amino acid and glutathione adducts of cis-2-butene-1,4-dial, a reactive metabolite of furan","volume":"10","author":"Chen","year":"1997","journal-title":"Chem. Res. Toxicol."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0270","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ab.2006.01.016","article-title":"A quantitative high-throughput trapping assay as a measurement of potential for bioactivation","volume":"51","author":"Meneses-Lorente","year":"2006","journal-title":"Anal. Biochem."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0275","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1021\/tx0501637","article-title":"Cyanide trapping of iminium ion reactive intermediates followed by detection and structure identification using liquid chromatography-tandem mass spectrometry (LC-MS\/MS)","volume":"18","author":"Argoti","year":"2005","journal-title":"Chem. Res. Toxicol."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0280","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/rcm.3953","article-title":"Rapid detection and characterization of reactive drug metabolites in vitro using several isotope-labeled trapping agents and ultra-performance liquid chromatography\/time-of-flight mass spectrometry","volume":"23","author":"Rousu","year":"2009","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0285","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1124\/dmd.104.001842","article-title":"Metabolic activation of fluoropyrrolidine dipeptidyl peptidase-IV inhibitors by rat liver microsomes","volume":"33","author":"Xu","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0290","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1021\/tx700344m","article-title":"Peptide-based in vitro assay for the detection of reactive metabolites","volume":"21","author":"Mitchell","year":"2008","journal-title":"Chem. Res. Toxicol."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0295","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1124\/dmd.108.021725","article-title":"Covalent binding and tissue distribution\/retention assessment of drugs associated with idiosyncratic drug toxicity","volume":"36","author":"Takakusa","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0300","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1021\/tx800161s","article-title":"Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose","volume":"21","author":"Obach","year":"2008","journal-title":"Chem. Res. Toxicol."},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0305","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/hep.22272","article-title":"Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals","volume":"47","author":"Lammert","year":"2008","journal-title":"Hepatology"},{"key":"10.2133\/dmpk.DMPK-10-RV-090_bb0310","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1124\/dmd.109.027797","article-title":"A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding","volume":"37","author":"Nakayama","year":"2009","journal-title":"Drug Metab. Dispos."}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715305486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715305486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T22:30:53Z","timestamp":1740781853000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436715305486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"alternative-id":["S1347436715305486"],"URL":"https:\/\/doi.org\/10.2133\/dmpk.dmpk-10-rv-090","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2011]]}}}